Compare Novavax Inc (NVAX) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Philip Morris International Inc. — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Philip Morris International Inc. trades at $188.45 (market cap $300.37B). The key difference: Philip Morris International Inc. is far larger — about 231.1× Novavax Inc's market cap, and Philip Morris International Inc. pays a 3.05% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PM | |
|---|---|---|
Market Cap | $1.30B | $300.37B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $192.98 |
52-Week Low | $6.22 | $144.33 |
Enterprise Value | $800.50M | $346.86B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.
The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
